Photo by nci from unsplash
Baker et al 1 raise many interesting points on the validity and use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria that I would like to… Click to show full abstract
Baker et al 1 raise many interesting points on the validity and use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria that I would like to reflect on. But first of all I would like to reiterate my main point, one which I think we agree on: In all clinical trials where remission is one of the outcomes, it should be defined according to the ACR/EULAR criteria. Baker et al list several concerns on these criteria that are well taken, and some that are generic to the way we measure disease activity today. Indeed, the ACR/EULAR criteria were developed with the express aim to define remission, more specifically ‘to develop a definition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials’. Although the committee was …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!